Upstream Bio, Inc. (UPB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US91678A1079
Upstream Bio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 2.85 m USD |
| Operating income | -160.36 m USD |
| EBIT | -160.38 m USD |
| Net income | -143.44 m USD |
| Diluted EPS – continuing operations | -2.66 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
More stocks
- HOOKER FURNISHINGS Corp (HOFT)
- Neousys Technology Inc. (6922.TWO)
- Able C&C (078520.KS)
- Nippon Indosari Corpindo Tbk (ROTI.JK)
- Masterflex (MZX.DE)
- Tri Ocean Textile Co Ltd (1472.TW)
- Vina San Pedro (VSPT.SN)
- Sandfire Resources America Inc (SFR.V)
- Yg Plus Inc (037270.KS)
- BINEX Co. Ltd (053030.KQ)
- Ferro S.A. (FRO.WA)
- Orvana Minerals Corp. (ORV.TO)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.